Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Pharma Industry Analysis

UpdatedMar 06, 2026
DataAggregated Company Financials
Companies319
  • 7D-3.0%
  • 3M6.8%
  • 1Y18.9%
  • YTD1.9%

Over the last 7 days, the Pharma industry has dropped 3.0%, driven by Eli Lilly declining 3.8%. In contrast, Liquidia has gained 12%. In the past year, the industry has gained 19%. As for the next few years, earnings are expected to grow by 11% per annum.

Industry Valuation and Performance

Has the U.S. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 06 Mar 2026US$2.4tUS$406.1bUS$72.5b18.8x32.5x5.8x
Sun, 01 Feb 2026US$2.3tUS$405.1bUS$73.9b20.4x31.1x5.7x
Tue, 30 Dec 2025US$2.3tUS$402.8bUS$71.4b19.9x31.7x5.6x
Thu, 27 Nov 2025US$2.3tUS$402.7bUS$71.4b20.6x31.6x5.6x
Sat, 25 Oct 2025US$1.9tUS$389.2bUS$63.5b17.7x29.7x4.8x
Mon, 22 Sep 2025US$1.8tUS$387.9bUS$60.9b18.4x29x4.6x
Wed, 20 Aug 2025US$1.7tUS$387.8bUS$61.1b19.1x28.4x4.5x
Fri, 18 Jul 2025US$1.8tUS$384.0bUS$62.1b18x28.5x4.6x
Sun, 15 Jun 2025US$1.8tUS$382.7bUS$61.2b17.8x29.1x4.7x
Tue, 13 May 2025US$1.7tUS$382.6bUS$61.0b17.1x27.1x4.3x
Thu, 10 Apr 2025US$1.6tUS$379.9bUS$40.6b16.1x40.1x4.3x
Sat, 08 Mar 2025US$2.0tUS$381.1bUS$39.2b16.5x49.8x5.1x
Mon, 03 Feb 2025US$1.9tUS$370.4bUS$29.8b18.4x62x5x
Wed, 01 Jan 2025US$1.8tUS$369.3bUS$31.3b16.5x56.9x4.8x
Fri, 29 Nov 2024US$1.9tUS$373.8bUS$30.6b19.8x60.9x5x
Sun, 27 Oct 2024US$2.0tUS$365.3bUS$23.7b17.9x83.2x5.4x
Tue, 24 Sep 2024US$2.0tUS$364.2bUS$25.3b18.9x80.4x5.6x
Thu, 22 Aug 2024US$2.0tUS$362.1bUS$21.8b18x93.3x5.6x
Sat, 20 Jul 2024US$1.9tUS$356.5bUS$13.1b15.9x148.2x5.4x
Mon, 17 Jun 2024US$1.9tUS$358.3bUS$14.1b15.3x137.4x5.4x
Wed, 15 May 2024US$1.9tUS$358.2bUS$13.8b18.1x134.6x5.2x
Fri, 12 Apr 2024US$1.8tUS$355.1bUS$23.9b23.4x76.9x5.2x
Sun, 10 Mar 2024US$1.9tUS$355.3bUS$22.4b22.5x84x5.3x
Tue, 06 Feb 2024US$1.8tUS$352.8bUS$22.8b28.1x79.4x5.1x
Thu, 04 Jan 2024US$1.8tUS$375.2bUS$33.8b27.7x51.7x4.7x
Sat, 02 Dec 2023US$1.7tUS$375.2bUS$33.9b27.2x48.6x4.4x
Mon, 30 Oct 2023US$1.6tUS$383.5bUS$46.6b14.2x34.1x4.1x
Wed, 27 Sep 2023US$1.7tUS$381.8bUS$43.9b18.5x38.1x4.4x
Fri, 25 Aug 2023US$1.8tUS$381.6bUS$44.1b19.8x39.9x4.6x
Sun, 23 Jul 2023US$1.7tUS$394.3bUS$60.5b18.6x28.7x4.4x
Tue, 20 Jun 2023US$1.7tUS$392.8bUS$60.1b19x29x4.4x
Thu, 18 May 2023US$1.7tUS$393.1bUS$60.5b18.7x28.4x4.4x
Sat, 15 Apr 2023US$1.7tUS$401.3bUS$68.5b17.5x24.3x4.2x
Mon, 13 Mar 2023US$1.5tUS$401.1bUS$69.5b17.4x21.9x3.8x
Price to Earnings Ratio

21.9x


Total Market Cap: US$1.5tTotal Earnings: US$69.5bTotal Revenue: US$401.1bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Pharma Industry Price to Earnings3Y Average 53.4x202420252026
Current Industry PE
  • Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 32.5x which is lower than its 3-year average PE of 53.4x.
  • The 3-year average PS ratio of 4.9x is lower than the industry's current PS ratio of 5.8x.
Past Earnings Growth
  • Both revenue and earnings for companies in the Pharmaceuticals industry have remained mostly flat over the last three years.
  • This means that sales and the cost of doing business have remained relatively consistent over this period and subsequently, so have profits.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-1.24%
Healthcare-2.78%
Pharma-2.97%
Pharma-2.97%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LQDA LiquidiaUS$34.5212.1%
+US$324.5m		132.3%PS19x
LGND Ligand PharmaceuticalsUS$206.275.1%
+US$252.3m		77.8%PE33.1x
MANE VeradermicsUS$48.6213.3%
+US$213.2m		n/aPE-29.5x
TRVI Trevi TherapeuticsUS$13.0813.5%
+US$200.0m		204.9%PB8.8x
NKTR Nektar TherapeuticsUS$72.459.9%
+US$183.3m		460.8%PS32.4x

Latest News

JNJ
US$239.63
Johnson & Johnson
7D
-1.6%
1Y
44.5%
LQDA
US$34.52
Liquidia
7D
12.1%
1Y
132.3%
LLY
US$983.26
Eli Lilly
7D
-3.8%
1Y
7.7%
TRVI
US$13.08
Trevi Therapeutics
7D
13.5%
1Y
204.9%

Chronic Cough Platform And Strong Cash Runway Will Support Future Upside Potential

Catalysts About Trevi Therapeutics Trevi Therapeutics is a clinical stage biopharmaceutical company developing Haduvio, an extended release formulation of nalbuphine, for multiple chronic cough indications where there are currently no FDA approved therapies. What are the underlying business or industry changes driving this perspective?
ZTS
US$122.23
Zoetis
7D
-5.8%
1Y
-26.9%
TEVA
US$31.75
Teva Pharmaceutical Industries
7D
-6.0%
1Y
106.8%

TEVA: Affordable Medicines And 2026 Pipeline Catalysts Will Drive Bullish Outlook

Analysts have nudged their price target for Teva Pharmaceutical Industries up to $38 from $37, reflecting a slightly higher fair value estimate and updated assumptions around long term revenue growth, margins, and the potential for duvakitug to reach $3b in peak sales following recent Phase 2 data with Sanofi. Analyst Commentary Recent research updates on Teva Pharmaceutical Industries highlight a mix of enthusiasm around the pipeline and affordability theme, alongside caution around execution risk and legal overhangs.
NKTR
US$72.45
Nektar Therapeutics
7D
9.9%
1Y
460.8%

NKTR: Rezpeg Durability In Atopic Dermatitis And Alopecia Will Drive Future Upside

Analysts have lifted their price targets on Nektar Therapeutics, with one moving from $105 to $150, citing stronger conviction in Rezpeg's durability data in Atopic Dermatitis and alopecia areata, a clearer financing profile, and a more supportive catalyst path that is reflected in a higher fair value estimate of about $130 per share. Analyst Commentary Bullish Takeaways Bullish analysts point to the 52 week maintenance data from the REZOLVE AD study as reinforcing confidence in Rezpeg's durability, which they see as a key input to their higher fair value estimates.
RPRX
US$45.68
Royalty Pharma
7D
0.7%
1Y
37.3%
OCUL
US$10.33
Ocular Therapeutix
7D
7.7%
1Y
40.7%

OCUL: Higher Sanofi Bid And SOL-1 Data Will Drive Bullish Repricing

The analyst price target for Ocular Therapeutix has been adjusted from $20 to $18 as analysts factor in updated fair value estimates, along with views that Axpaxli data from the SOL-1 trial supports potential durability and safety in the large wet AMD market. Analyst Commentary Recent Street research reflects a mixed but generally supportive stance toward Ocular Therapeutix following the SOL-1 trial readout.
MRK
US$116.07
Merck
7D
-2.7%
1Y
23.5%
PFE
US$26.61
Pfizer
7D
-1.8%
1Y
1.4%
LGND
US$206.27
Ligand Pharmaceuticals
7D
5.1%
1Y
77.8%
ELAN
US$23.92
Elanco Animal Health
7D
-8.7%
1Y
120.9%
TERN
US$42.00
Terns Pharmaceuticals
7D
2.6%
1Y
1,057.0%
RGC
US$24.21
Regencell Bioscience Holdings
7D
-7.9%
1Y
21,690.2%

Regencell Bioscience Holdings Ltd. (RGC) The TCM Biotech Lottery Ticket: High Hopes and Extreme Volatility

If you're looking for a stock that perfectly embodies the wild, speculative side of the market for your viewers, Regencell Bioscience (RGC) is it. As of late February 2026, this Hong Kong-headquartered, early-stage bioscience company is trading around $29.17 , following a period of mind-bending volatility where the stock surged thousands of percent over the past year.
MANE
US$48.62
Veradermics
7D
13.3%
1Y
n/a